Stay updated on DESTINY-B12 Clinical Trial
Sign up to get notified when there's something new on the DESTINY-B12 Clinical Trial page.

Latest updates to the DESTINY-B12 Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.4%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check41 days agoChange DetectedThe webpage has been updated to include new clinical trial results and metrics related to the treatment of HER2-positive metastatic breast cancer, specifically focusing on participants with and without brain metastasis. Key metrics such as Objective Response Rate (ORR), Progression-Free Survival (PFS), and survival rates have been added, while previous data points have been removed.SummaryDifference76%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check77 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study descriptions and eligibility criteria for a clinical trial on Trastuzumab deruxtecan, while adding new identifiers and collaborators related to breast cancer research.SummaryDifference24%
Stay in the know with updates to DESTINY-B12 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DESTINY-B12 Clinical Trial page.